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Abstract
Breast cancer is one of the leading causes of cancer-related mortality of
women in the United States. Since the majority of cancer deaths are due to
metastases rather than the primary tumor, a better understanding of the
biological mechanisms that lead to metastatic disease is critical to reduce
breast cancer associated mortality. Current adjuvant therapies use the same
broadly cytotoxic and targeted strategies against metastases as are used
against the primary tumor. However, resistance to chemotherapy due to the
cellular dormancy, high genotypic and phenotypic heterogeneity between
primary tumor and metastases as well as among individual metastases, and the
limitations in detection of disseminated tumor cells and micrometastases
significantly hinder the efficiency of currently available therapies. While it is
crucial to directly address the issue of metastatic dormancy and evaluate for
anti-metastatic therapy the relevance of molecular targets chosen based on
primary tumor profiling, it is also imperative to address metastasis-specific
mechanisms of growth and survival that are likely to be distinct from those of
the primary tumor. We believe that a three-pronged approach to therapy will be
necessary to deal with progressive disease: blocking of further dissemination
after diagnosis; eradication of disseminated tumor cells and prevention of the
dormant-to-proliferative switch of those remaining; and elimination of
established metastatic tumors. The implementation of this strategy requires a
greater depth of knowledge of metastasis driver and maintenance genes and
suggests the need for a “Metastasis Genome Atlas” project to complement the
current investigations into cancer genomic landscapes.
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Introduction
Breast cancer remains one of the leading causes of cancer-related 
mortality among women in the US1. Since the primary tumor is 
usually resected upon detection, the majority of mortality is due to 
metastases. While 5-year relative survival for patients diagnosed 
with localized breast cancer is 98.5%, it plummets to a dismal 25% 
for patients with distant overt metastases1. Moreover, an estimated 
20–50% of breast cancer patients diagnosed at an early stage are 
expected to develop metastatic disease, which can occur years or 
even decades after surgical removal of the primary tumor2. These 
statistics indicate that the establishment of effective therapies that 
target and prevent metastasis is of critical importance. Although the 
past decade has seen significant advances in the development of 
methods for detection and treatments of primary breast cancer, these 
treatments are generally ineffective at eliminating metastatic disease. 
This suggests either an inherent biological difference between pri-
mary tumors and distant metastases, a role of the microenvironment at 
the secondary site in inducing therapeutic resistance, or likely both.
Recent progress in breast cancer treatment has been characterized 
by a shift from cytotoxic drugs, which broadly target highly prolif-
erating cells, to more targeted therapies designed to attack a spe-
cific molecule or pathway through a known mechanism of action. 
This approach has been possible due to enormous technological 
leaps in genome sequencing, molecular biology, cancer genetics, 
genomics, and bioinformatics that allow for the identification of 
individual patient mutations and clinically actionable targets from 
tumor biopsy samples. Sequence information and patient-derived 
xenograft methods have shown promise in identifying individual-
ized therapeutic strategies that are effective for specific patients, 
rather than the traditional population-based clinical strategies. 
However, while various sequencing projects have characterized 
the genomic landscape of breast cancer3,4, relatively little is known 
about the somatic diversity of metastatic tumors. Expression pro-
filing has revealed multiple subtypes with different prognostic 
outcomes5 and led to identification of gene signatures that can strat-
ify patients into groups with low- or high-risk for developing distant 
metastatic disease6. Still, targeted therapies against metastases have 
proven to be more challenging to develop compared to those target-
ing the primary tumor, since the critical driver molecules have not 
yet been firmly established.
In this review, we discuss the major challenges facing the develop-
ment of efficient therapies against metastasis. We also present a strat-
egy that we believe will improve the targeting of metastatic disease: 
blocking of further dissemination after diagnosis, eradication of dis-
seminated tumor cells and prevention of the dormant-to-proliferative 
switch of those cells not eradicated, and elimination of established 
metastatic tumors. This strategy requires the elucidation of mecha-
nisms that drive the establishment and maintenance of metastases.
Current anti-metastatic treatments and therapies in 
development
Current therapies against metastatic breast cancer address differ-
ent stages of tumor progression7. Broad-spectrum therapies, such as 
cytotoxic chemotherapy, aim to kill actively dividing cancer cells. 
According to an extensive meta-analysis, combination chemotherapy 
can increase the 15-year survival rate of patients with early breast 
cancer8. However, a substantial number of these patients develop 
metastases or recurrent disease years after cessation of treatment, 
indicating the presence of dormant cells at the secondary site that 
are resistant to standard therapies. Therefore, the pathways that 
allow cancer cells to remain viable in a dormant state would pro-
vide ideal targets for eliminating minimal residual disease and 
preventing metastatic outgrowth after the cessation of treatment. 
Among them are the survival pathways involving Src and p389–12. 
Recent findings have shown that pharmacological inhibition of Src 
family kinase (SFK) signaling inhibited the proliferative outgrowth 
of dormant disseminated cells and the development of macrometa-
static lesions12. Furthermore, dormant cell proliferation required 
ERK1/2 activation, and the treatment of cells undergoing the 
dormant-to-proliferative switch with the combination of Src inhibi-
tor (AZD0530, saracatinib, AstraZeneca) and MEK1/2 inhibitor 
(AZD6244, selumetinib, AstraZeneca) resulted in apoptosis of 
dormant cells; neither of the inhibitors alone achieved this effect. 
Since MEK1/2 is a well-described upstream activator of ERK1/2, 
these observations complement previous reports showing that an 
ERKlow/p38high signaling ratio promotes tumor cell quiescence 
through a combination of signaling pathways promoting adaptive and 
basal survival and G0-G1 quiescence11. These reports indicate that 
therapies targeting signaling involved in the dormant-to-proliferative 
switch might represent promising clinical interventions against 
metastatic disease.
Major efforts of the pharmaceutical industry are now focused 
on the development of novel targeted therapies that function in a 
molecule-specific manner7. Examples of targeted therapies that are 
presently in clinical use for breast cancer are aromatase/estrogen 
synthase inhibitors (anastrozole, letrozole, and exemestane)13 and 
trastuzumab (Herceptin®), a monoclonal antibody against epidermal 
growth factor receptor 2 (ERBB2/HER2/neu)14. Initially investi-
gated as a monotherapy and later in combination with chemotherapy, 
trastuzumab significantly improved patient response rate, time 
to progression, and overall survival compared to chemotherapy 
alone14. However, its use is limited only to HER2-positive breast 
cancers, the expression of which, as explained in the next section 
of this review, may not be constant between primary tumors and 
metastases, reducing the effectiveness of this strategy.
Based on their specific role in the metastatic cascade, potential 
molecular targets for therapeutic intervention can be categorized 
as involved in either metastasis initiation or progression15,16. Due 
to the early dissemination of tumor cells, which is discussed in the 
next section, molecules important in metastasis initiation, such as 
regulation of cellular motility, angiogenesis, and invasion of local 
extracellular matrix (ECM), may not be efficient targets for pre-
venting metastatic disease since patients at risk already have dis-
seminated cells by the time of primary tumor diagnosis. However, if 
those molecules also play key roles in the later stages (progression) 
of metastasis, such as continued trafficking after initial escape from 
the primary tumor17, their targeting might be of clinical importance. 
In particular, molecules that promote survival at the distant sites, 
the dormancy-to-proliferation switch, and colonization of distant 
organs are very attractive targets for drug development.
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The molecules identified and currently being investigated comprise 
both the tumor cell autologous factors, such as those involved in 
signal transduction, adhesion, motility, growth and survival, and 
the microenvironmental factors, including resident stromal cells, 
components of the immune system, chemokines, and promoters 
of angiogenesis. A growing catalog of potential molecular targets 
identified for inhibition of metastatic progression has been exten-
sively reviewed7,18,19, including a recent overview of drug candidates 
in current pharmaceutical pipelines that target the mechanisms of 
tumor cell migration20. Effective anti-metastatic therapies need to 
address metastasis-specific characteristics that allow for the active 
targeting of metastatic cells. In the next section, we will discuss in 
more detail the challenges facing the treatment of metastasis from 
the perspective of drug development, specifically heterogeneity 
within and between metastases, as well as between metastases and 
primary tumors, constraints in detection and analysis, and the tim-
ing of intervention.
Challenges in the treatment of metastatic disease
Dissemination
The logical approach to preventing metastatic disease is to inhibit 
the initial dissemination step. Dissemination used to be considered 
a late-stage event in the linear model of malignant disease evolution, 
due to the time necessary to accumulate essential somatic mutations 
required by tumor cells for motility and survival beyond the pri-
mary site. However, evidence from mouse models of spontaneous 
mammary tumorigenesis has shown that tumor cells are able to dis-
seminate to the bone marrow as early as four weeks of age, when 
mammary tissue only appears in atypical ductal hyperplasia (ADH) 
or ductal carcinoma in situ (DCIS) stages21. Lung micrometastases 
in the BALB-NeuT model were found at 20 weeks, a full 3 weeks 
before tumors became visibly invasive. Additionally, early dissemi-
nated tumor cells (DTCs)—cells that left the primary tumor and 
spread to another tissue via the circulation—could be released from 
growth arrest and had the capability to develop into metastases. The 
clinical relevance of these findings was confirmed using bone mar-
row samples from 607 breast cancer patients at various stages of 
disease, concluding that small tumors produced similar numbers 
of DTCs to late-stage tumors. Other evidence, including metasta-
sis without invasive cancer such as DCIS22, cancers of unknown 
primary origin23, and accidental transfer of cancer from clinically 
disease-free organ donors24 all supported the authors’ observations 
of early dissemination. These reports suggest that breast cancer 
patients likely have DTCs even before their primary cancer is diag-
nosed, making the targeting of the origin of metastatic disease a less 
promising therapy option.
Metastatic dormancy
One of the major challenges facing oncologists, particularly in the 
case of breast cancer, concerns DTCs that remain in tissues after 
adjuvant therapy in a sub-clinical, currently undetectable state, 
known as dormancy. Upon dissemination, cancer cells can enter 
dormancy either as individual non-proliferative, quiescent cells 
or as undetectable micrometastases held in a reduced or balanced 
proliferative/apoptotic state by lack of adequate resources (ang-
iogenic dormancy) or an active immune system (immunogenic 
dormancy)25,26. These cells or micrometastases can eventually 
re-emerge and become proliferative years after a patient is thought 
to be cancer-free. Since the mechanisms of action of many cyto-
toxic therapies disrupt aspects of the mitotic process, these agents 
are most likely ineffective against the low or non-proliferative dor-
mant cells27. There is also accumulating evidence from experimental 
models that activated survival mechanisms may be playing a role 
in protecting DTCs25. Regardless of the exact mechanism, DTCs 
are resistant to the broad-spectrum therapeutic strategies currently 
in use. Targeted therapy may provide additional benefit, but thera-
peutic regimens based on the primary tumor may not be effective 
in DTCs.
Heterogeneity between primary tumor and metastases
Accumulating evidence indicates that metastases can be geneti-
cally and phenotypically different from the primary tumor28. This 
phenomenon has been reported for overt metastases that exhibit 
the opposite estrogen receptor, progesterone receptor, or HER-2 
expression profile of the primary tumor. A meta-analysis examin-
ing estrogen receptor, progesterone receptor, and/or HER-2 expres-
sion in patients’ primary breast tumors and matched recurrent 
metastases included 48 studies published between 1983 and 201129 
showing 20%, 33%, and 8% discordance for estrogen receptor, pro-
gesterone receptor, and HER-2 status, respectively, with a higher 
prevalence of positive to negative conversion. The authors suggest 
that this observation may be the result of individual DTCs reflecting 
heterogeneity of receptor expression within the primary tumor. Fol-
lowing endocrine therapy, the remaining resistant subpopulations of 
primary tumor cells are selectively able to disseminate to and grow 
at secondary sites, producing metastases with a different receptor 
expression profile than the majority of the original primary tumor. 
Since treatments are often determined based on the characteristics 
of the primary tumor, discordance between the primary tumor and 
metastatic phenotypes can render the treatment ineffective against 
DTCs. Conversely, some patients with receptor-negative primary 
tumors but positive metastases may benefit from available targeted 
therapies but currently are unlikely to receive these therapeutic 
options due to the clinical characteristics of the primary tumor.
Heterogeneity amongst metastases
In addition to differences between primary and metastatic tumors, 
there is also heterogeneity among individual metastases. More than 
one million cells per gram of tumor can be shed from the primary 
mass every day30 and these cells can come from any of the diverse 
subpopulations that compose the tumor at any point during tumor 
evolution. Therefore, the DTCs are a genetically and phenotypi-
cally heterogeneous group. However, not all of these cells have the 
ability to grow into clinically relevant distant lesions, otherwise 
every patient would have a high metastatic burden. In reality, the 
metastatic process is incredibly inefficient31,32, suggesting a great 
deal of selective pressure is experienced by DTCs and only those 
with the proper combination of characteristics are able to success-
fully colonize a secondary site. Though the successfully metastatic 
cells probably share many characteristics, the genetic changes that 
underlie those characteristics may not be identical, resulting in 
heterogeneity between metastases in addition to differences from 
the primary tumor33. Similar to the evaluation of HER-2 expres-
sion between primary tumor and metastases discussed earlier, an 
investigation into HER-2 expression revealed that 18% of metas-
tases within the same patient showed discordant expression34. In 
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another examination of single primary and metastatic breast cancer 
cells using immunofluorescence in situ hybridization (iFISH), can-
cer subtype markers, and statistical analysis, investigators measured 
genetic and phenotypic heterogeneity between distant metastases35. 
These results indicated significant diversity between distant metas-
tases within the same patient. Furthermore, the authors observed 
substantial differences between metastases in the proportions of 
cells displaying subtype markers, indicating both genetic and phe-
notypic differences were prevalent between distant metastases from 
the same patient.
Pharmacokinetics
An additional challenge to successful treatment of metastatic dis-
ease is the ability to deliver the therapy to the metastatic tumor 
cells. Metastases are often present in multiple sites within a patient 
and drug accessibility between tissues, for example bone versus 
lung, may be significantly different. Certain tissues may act as 
“pharmacological sanctuaries” that protect cancer cells from avail-
able therapies due to barriers that prevent access to those cells. 
Evidence suggests that at least some brain metastases are shielded 
from pharmacologic intervention by the blood-brain barrier36. To 
cure patients of metastatic disease, effective therapies will have to 
be deliverable to all of the potential metastatic sites within the body. 
Since microenvironments differ in various secondary sites, combi-
nation anti-metastasis therapies may be necessary to deal with both 
intra-tumoral genetic heterogeneity as well as microenvironmentally-
induced heterogeneity.
In summary, current adjuvant therapies are expected to control 
metastasis by targeting residual disease remaining after surgery. 
However, the use of adjuvant therapy is estimated to reduce the 
relative risk of relapse by only 19–37% depending on the age of 
the patient37. Thus, neither the current cytotoxic nor targeted adju-
vant approaches appear to be as effective at preventing metastases 
as they are at targeting the primary tumor. Finding new molecular 
targets for preventing the growth of metastatic tumors should be 
based on the realization of how different this process is from early 
tumorigenesis.
Take-home lessons for optimal design of future anti-
metastatic therapies
Based on our current knowledge of metastasis biology, we envision 
a three-pronged strategy for clinical intervention for progressive dis-
ease: prevention, stasis, and destruction. The prevention arm would 
be primarily applied as a neo-adjuvant therapy intended to reduce 
the potential metastatic capacity of tumor cells naturally shed from 
the primary tumor between diagnosis and surgical removal. As dis-
cussed above, this might require combination therapy for maximal 
efficiency since it has been demonstrated that tumor cells use mul-
tiple motility mechanisms (amoeboid, epithelial-to-mesenchymal 
transition, collective migration38) to initiate dissemination. This arm 
might also be used to help suppress potential metastatic cells dis-
placed during surgical resection itself. Since breast cancers undergo 
early dissemination, the prevention strategy would not necessarily 
be effective against cells that disseminated to distant sites prior to 
diagnosis. For these cells, cytostatic or cytotoxic therapies need to 
be developed, specific to the biology of disseminated cells, to either 
hold the disseminated cells in a sub-clinical state for the remaining 
natural lifetime of the patient, or to eliminate the metastatic “seed” 
before it can establish clinically relevant lesions. Finally, for those 
patients unfortunate enough to develop metastases, therapeutics 
specifically developed and targeted to metastatic biology need to be 
developed to reduce morbidity and mortality associated with these 
secondary tumors.
For these strategies to work, appropriate targets that drive the 
establishment and maintenance of metastasis have to be identified. 
Regrettably, despite significant advances in our understanding of the 
cellular biology of metastatic disease, our knowledge of metastasis 
“driver” genes remains limited. This is due partially to the difficulty 
of studying the process, since much of the important biology occurs 
in a small fraction of disseminated single cells or micrometastases. 
At present, it is not possible to easily identify those cells that will 
evolve into macroscopic lesions for in depth analysis, or exactly 
when that critical event occurs. In addition, metastatic samples are 
difficult to obtain from human patients since they are not usually 
resected, but instead are subject to systemic therapy. Thus, although 
the common mutations that drive primary breast cancer are now 
known thanks to large sequencing projects, much less is known 
about the mutational spectrum in metastatic disease. Finally, there 
may be many genes that are associated with metastatic progres-
sion. Analysis of gene expression-based prognostic signatures sug-
gests that there may be hundreds or even thousands of genes whose 
expression is correlated with the disease outcome39. Many of these 
genes are most likely expressed in the tumor microenvironment and 
therefore investigations solely in tumor cells have the potential to 
miss important molecules targetable for clinical intervention.
Continued investigations based on the biology of primary tumors 
for the development of novel therapeutics are clearly important, and 
undoubtedly will provide additional benefit to patients. However, this 
strategy is potentially fraught with dangers, since therapies that can 
shrink primary tumors have been shown to have little effect, or even 
potentially adverse effects, on metastatic disease40,41. Furthermore, 
work from many laboratories has identified metastasis-associated 
genes that are not frequently mutated during cancer progression 
but are epigenetically silenced or exert their metastatic influence 
through alterations at the transcriptional level. Our own laboratory 
uses a meiotic genetics approach to identify somatically inherited 
polymorphisms that affect patients’ susceptibility to metastasis. 
This approach has generated a growing list of metastasis suscep-
tibility genes with tumor-autonomous or stromal effects, includ-
ing some with the potential to be actionable clinical targets42–48. The 
results of these studies suggest that a more comprehensive exami-
nation of metastasis biology, incorporating both genomic and tran-
scriptional landscape mapping, may provide an entirely different 
set of genes that might be more advantageously targeted to specifi-
cally reduce metastatic burden, without necessarily impacting the 
primary tumor.
Now that The Cancer Genome Atlas (TCGA) and other genomics 
projects have provided detailed information regarding the etiology 
of primary tumors, it is time to initiate similar projects for meta-
static disease. Since metastatic tumors represent highly selected 
cells from a subset of the primary tumor localized in completely 
different microenvironments, these lesions should be recognized as 
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related (but distinct) tumors with different biology. Thus, treatment 
strategies that are developed based on specific features of metasta-
sis biology, used in parallel with those designed against the primary 
tumor, will provide a more effective method for combatting the 
final lethal stages of neoplastic disease than those strategies devel-
oped solely against the primary tumor. A Metastasis Genome Atlas 
Project would, however, have additional challenges compared to 
the TCGA. The major challenge would be access to the metastatic 
tumor samples since surgical resection of metastases is usually not 
performed due to increased risk without perceived patient benefit. 
In addition, metastatic tissue collected postmortem may be com-
promised or selected by therapies that potentially induce genomic 
changes, complicating analysis and interpretation of the results. 
Furthermore, it will be important to screen multiple metastases from 
different secondary sites within individual patients to help identify 
tissue-specific differences that might expose therapeutic vulnerabili-
ties or resistance. Regardless of the challenges facing the Metastasis 
Genome Atlas Project concept, improved therapeutic strategies to 
reduce breast cancer morbidity and mortality would significantly 
benefit from a better understanding of the biology underlying the 
primary cause of patient distress, disseminated metastatic disease.
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prevention of further spread, eradication of (or maintenance of dormancy in) disseminated cells and, most
important of all, destruction of established micrometastases.
The latter is certainly the main challenge: most primary breast cancers are successfully and completely
removed by surgery, it is the already-disseminated tumor cells (DTC) that are the potential seeds of
destruction of a human life. Much attention has been given to the early stages of metastasis: release of
cells, motility, invasion, adhesion to endothelia, extravasation – perhaps because these steps are the
easiest to manipulate experimentally. The onus is now on scientists to address whether any of these
processes and their molecular mediators are still required once DTC are established at secondary sites.
We need to know if they represent the ‘starter motor’ (essential initially but redundant once the process is
underway) or the ‘engine’ (powering the continued progress) of metastases. Even if we can prevent
further spread, it is important to define whether existing micrometastases (probably generated very early
in the course of the disease) would prove fatal before any later waves of circulating cells take hold –
possibly a case of shutting the stable door after the horse has bolted.
Metastases break one of the fundamental ‘taboos’ of multicellular organisms – that of cells being able to
survive and thrive in quite disparate, alien tissue environments – they no longer ‘know their place’. If we
could define how this is achieved we may discover some common denominator actionable molecular
targets for intervention that could be effective against widespread metastatic disease. Such studies, with
the precision tools of genetic manipulation could perhaps be achieved in lower organisms as a starting
point.
So, key additional questions raised by this interesting piece are: which if any of the molecular
mechanisms required to initiate and maintain primary tumors are also essential for establishing
metastases and for how long do any such dependencies persist? Or are the determinants of successful
secondary colonisation quite distinct? Do different organs have similar or unique requirements that enable
cancer cells to form overt metastases? The paper touches on these considerations, but much more
research is required in this challenging area. It is therefore essential, as Hunter rightly states, to facilitate
better access to clinical material, especially relapsed and drug resistant secondary disease (which may
only be practical at autopsy).
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and effectively this last hurdle in our efforts to improve cure rates in breast and other cancers.
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This is a thoughtful and well-written short review of a clinically very important topic. This review presents a
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